Pomaglumetad methionil
Phase 3Terminated 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Dec 1, 2011 โ Oct 1, 2012
NCT ID
NCT01487083About Pomaglumetad methionil
Pomaglumetad methionil is a phase 3 stage product being developed by Eli Lilly for Schizophrenia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01487083. Target conditions include Schizophrenia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01487083 | Phase 3 | Terminated |
Competing Products
20 competing products in Schizophrenia